Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.85 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | GMNN | O75496 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | PRKCG | P05129 | 1/20 | 0.71 |
| ▸ | PRKCB | P05771 | 1/20 | 0.71 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | PRKCH | P24723 | 1/20 | 0.71 |
| ▸ | AKT1 | P31749 | 1/20 | 0.71 |
| ▸ | PRKCI | P41743 | 1/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159631 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL15477814 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL233046 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL15477633 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL22693933 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL15477746 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL2221345 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL24563 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 | |
| SCHEMBL9951509 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | JADO TECHNOLOGIES GMBH | 2011-10-27 | — | — | US | claimed |
| US-20090018105-A1 | Means and Methods for the Treatment and Prevention of Allergic Diseases | JADO TECHNOLOGIES GMBH | 2009-01-15 | — | — | US | claimed |
| US-8394785-B2 | Methods for the treatment and amelioration of urticaria | JADO TECHNOLOGIES GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | JADO TECHNOLOGIES GMBH | 2011-10-27 | — | — | US | disclosed |
| US-7998945-B2 | Methods for the treatment and amelioration of atopic dermatitis | JADO TECHNOLOGIES GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090018105-A1 | Means and Methods for the Treatment and Prevention of Allergic Diseases | JADO TECHNOLOGIES GMBH | 2009-01-15 | — | — | US | disclosed |
| EP-1981488-A1 | MEANS AND METHODS FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES | Jado Technologies GmbH (DE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007071402-A1 | MEANS AND METHODS FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES | JADO TECHNOLOGIES GMBH (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018105-A1 | Means and Methods for the Treatment and Prevention of Allergic Diseases | PHOSPHO1, CPA3, SMPD3 | SMN1; SMN2 3518/4885NR5A2 4535/4885NR5A1 3261/4885 |
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | PHOSPHO1, SMPD3, SMPD1 | SMN1; SMN2 4002/4885NR5A2 4616/4885NR5A1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.